Growth hormone, insulin growth factor-1, and IGF binding protein-3 axis relationship with bone mineral density among healthy men

Archives of Andrology

Volumn 49, Issue 3, 2003, Pages 191-199

  Krassas, G E ^a   Papadopoulou, Ph ^a   Koliakos, G ^a   Konstantinidis, Th ^b   Kalothetou, K ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

BMI; Bone density; Growth hormone; Healthy males; Insulin growth factor 1; Insulin growth factor binding protein 3

Indexed keywords

BIOLOGICAL MARKER; GROWTH HORMONE; INSULIN GROWTH FACTOR 1; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE MINERAL; BONES OF THE EXTREMITIES; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FRACTURE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNORADIOMETRIC ASSAY; LUMBAR SPINE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; AGED; BLOOD; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RADIODENSITOMETRY; REFERENCE VALUE;

ADULT; AGED; BONE DENSITY; DENSITOMETRY, X-RAY; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 79961185288     PISSN: 01485016     EISSN: None     Source Type: Journal    
DOI: 10.1080/01485010390196724     Document Type: Article

References (26)

1. Bayer MF (1987): Performance criteria for appropriate characterization of "highly sensitive" thyrotropin assays. Clin Chem 33:630-631.
2. Bilezikian JP (1999): Osteoporosis in men, J Clin Endocrinol Metab 84:3431-3434.
3. Blum WF, Ranke MB (1990): Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res 33 (suppl 4):31-37.
4. Bouillon R, Herck EV, Jan L, Tan BK, Baelen HV, DeMoor P (1984): Two direct (nonchromatographic) assay for 25-hydroxyvitamin D. Clin Chem 30:1731.
5. Francis RM, Peacock M, Marshall DH, Horsman A, Aaron JE (1989): Spinal osteoporosis in men. Bone Miner 5:347-357.
6. Gillberg P, Johansson AG, Blum WF, Groth T, Ljunghall S (2001: Growth hormone secretion and sensitivity in men with idiopathic osteoporosis, Calcif Tissue Int 68:67-73.
7. Gillberg P, Olofsson H, Mallmin H, Blum WF, Ljunghall S, Nilsson AG (2002): Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP) -3 in Swedish men. Calcif Tissue Int 70:22-29.
8. Ismail AAA (1986): The role of testosterone measurements in the investigation of androgen disorders. Ann Clin Biochem 23:113-34.
9. Jackson JA, Kleerekoper M (1990): Osteoporosis in men: diagnosis, pathophysiology and prevention. Medicine 69:139-152.
10. Janssen JAMJL, Burger H, Stolk RP, Grobbee DE, de Jong FH, lamberts SWJ, Pols HAP (1998): Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol 138:627-632.
11. Johansson AG, Forslund A, Hambraeus L, Blum WF, Ljunghall S (1994): Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men. J Bone Miner Res 9:915-921.
12. Jones JI, Clemmons DR (1995): Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-32.
13. Kanis JL, Melton LS, Christiansen C, Johnston CC, Khaltaev N (1994): The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141.
14. Krassas GE, Papadopoulou FG, Doukidis D, Konstantinidis Th, Kalothetou K (2001): Age-related changes in bone density among healthy Greek males. J Endocrinol Invest 24:326-333.
15. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, Bilezikian JP (1997): Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 82:2799-2805.
16. Ljunghall S, Johansson AG, Burman P, Kampe O, Lindh E, Karlsson FA (1992): Low plasma levels of insulin-like growth factor I (IGF-I) in male patients with idiopathic osteoporosis. J Intern Med 232:59-64.
17. Nussbaum SR, Zahrandik RJ, Lavigne JR (1987): Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367.
18. Orwoll ES, Klein RF (1995): Osteoporosis in men. Endocr Rev 16:87-115.
19. Parfitt AM, Duncan H (1982): Metabolic bone disease affecting the spine. In: Spine. Roteman R (ED). Philadelphia: WB Saunders, p. 775.
20. Pfeilschifter J, Ziegler R (1998): Relationship between IGF-I and skeletal aging. Eur J Endocrinol 138:617-618.
21. Reed BY, Zerwekh JE, Sakhaee K, Breslau NA, Gottschalk F, Pak YC (1995): Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria. J Bone Miner Res 10:1218-1224.
22. Resch H, Pietschmann P, Woloszczuk W, Krexner E, Bernecher P, Willvonseder R (1992): Bone mass and biochemical parameters of bone metabolism in men with spinal osteoporosis. Eur J Clin Invest 22:542-545.
23. Seek T, Scheppach B, Scharla S, Diel I, Blum WF, Bismar H, Schmid G, Krempien B, Ziegler R, Pfeilschifter J (1998): Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre-and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab 83:2331-2337.
24. Seeman E, Melton LJ, O' Fallon WM, Riggs BL (1983): Risk factors for spinal osteoporosis in men. Am J Med 75:977-983.
25. World Health Organization (1994): Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series No 843. Geneva: WHO.
26. Wuster C, Blum WF, Schlemilch S, Ranke MB, Ziegler R (1993): Decreased Serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. J Intern Med 234:249-255.